EDX Medical Group PLCAQUIS: EDX

EDX Medical Group: Director/PDMR Shareholding

· Issued by EDX Medical Group PLC via RNS

Summary by 6ix AI

On November 13, 2026, Dr Michael Hudson, Chief Executive Officer and a director of EDX Medical Group plc, sold shares from his share dealing account and bought shares into his individual savings account (ISA). The company, which develops and supplies digital diagnostic products and services for disease detection and treatment, was notified on November 16, 2026.

Key details

  • He sold 193,439 ordinary shares of 1p at 7.75 pence per share from his share dealing account.
  • He bought 193,568 ordinary shares at 7.75 pence per share into his ISA account.
  • After the transfer, Dr Michael Hudson's total interest in the company is 20,750,129 shares, representing 4.81% of the company's total voting rights.
  • The trades took place on the AIM market, where EDX Medical Group plc's shares are listed.

6ix AI wrote this summary from the release below and checked it against the release.

EDX Medical Group PLC
16 November 2026

A blue hexagon with white x and blue x Description automatically generated with low confidence

16 November 2026

EDX Medical Group plc

("EDX Medical" or the "Company")

'Bed & ISA' share transfer & share purchase

CAMBRIDGE, UK: EDX Medical Group plc, which develops and supplies innovative digital diagnostic products and services to improve the early detection and treatment of major diseases, announces the Company was notified today that on 13 November 2026 Dr Michael Hudson, Chief Executive Officer and Director of the company, performed a 'Bed and ISA' transfer.

Dr Michael Hudson sold 193,439 ordinary shares of 1p from his share dealing account at a price of 7.75 pence per share and purchased 193,568 into his ISA account at a price of 7.75 pence per share.

As a result, Dr Michael Hudson's total interest in the Company is 20,750,129 representing 4.81% of the total voting rights of the Company.

1

Details of PDMR / person closely associated with them (“PCA”)

(a)

Name

Dr Michael Hudson

2

Reason for the notification

(a)

Position/status

PDMR / CEO

(b)

Initial notification/amendment

Initial Notification

3

Details of the Issuer

(a)

Name

EDX Medical Group plc

(b)

Legal Entity Identifier code

213800BZVJZTMCZ6DJ63

4

Details of the transaction(s)

(a)

Description of the financial instrument

Ordinary shares of £0.01 each

(b)

Identification Code

ISIN: GB00BNDMJS47

(c)

Nature of the transaction

  1. Sale of ordinary shares
  2. Purchase of Ordinary shares into ISA

(d)

Currency

GBP

(e)

Price(s) and volume(s)

Price(s)

Volume(s)

(1)

7.75p

193,439

(2)

7.75p

193,568

(f)

Aggregated information

- Aggregated volume

- Price

n/a

(g)

Date of the transaction

13-11-2026

(h)

Place of the transaction

XLON:AIMX

Contacts:

Canaccord Genuity Limited (Nominated Adviser and Broker)

Stuart Andrews

+44 (0) 20 7523 8318

Media House International

Ramsay Smith

Gary McQueen

+44 (0)7788 414856

ramsay@mediahouse.co.uk

+ 44 (0)7834 694609

gary@mediahouse.co.uk

IFC Advisory (Investor Relations)

Tim Metcalfe

Graham Herring

+44 (0) 203 934 6630

Notes for Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the AIM market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

EDX Medical Group PLC on 6ix

Earlier from EDX Medical

Later from EDX Medical

All EDX Medical news releases